

Journal Club Spotlights: Current Advancements in Non-Small Cell Lung Cancer



Key Concepts

ARROW Study

- Pralsetinib, an oral RET fusion targeting inhibitor, demonstrates robust clinical efficacy (response rates, duration of response, progression-free survival, and overall survival) in patients with RET fusion-positive metastatic non-small cell lung cancer, including patients who are treatment naïve or who previously received platinum-based therapy.
- Cytopenias and risk of infection are key adverse events to monitor in patients receiving pralsetinib. Other important adverse events related to pralsetinib include hypertension and elevated liver enzymes. Appropriate awareness, education, and monitoring/management strategies are vital to effective treatment and maintaining patients on therapy.